logo

For the Inventor, By the Inventor

Taipei, Taiwan

Shih-Che Hsu

This inventor holds 1 USPTO granted patent. Top assignee: Seismic Pharmaceuticals. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shih-Che Hsu. Retrieved from https://idiyas.com/inventor/shih-che-hsu-2iepacet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:

goldMedal1 out of 1 
 
Seismic Pharmaceuticals
 patent

Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents
1. 12503484 - Androstane derivatives with activity as pure or predominantly pure stimulators of SERCA2a for the treatment of heart failure (2025-12-23),

Title: Innovations of Shih-Che Hsu in Heart Failure Treatment

Introduction

Shih-Che Hsu is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of heart failure. His innovative work has led to the development of compounds that could potentially improve the lives of many patients suffering from this condition.

Latest Patents

Shih-Che Hsu holds a patent for "Androstane derivatives with activity as pure or predominantly pure stimulators of SERCA2a for the treatment of heart failure." This patent discloses compounds and compositions aimed at activating SERCA2a, which is crucial for heart function. The compounds are designed to act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na/KATPase. The disclosed compounds are derivatives of androstane, having a specific formula that enhances their effectiveness in treating heart failure.

Career Highlights

Hsu is currently associated with Seismic Pharmaceuticals, where he continues to innovate in the pharmaceutical sector. His work focuses on developing new treatments that can significantly impact patient care in cardiology. With a patent portfolio that includes 1 patent, Hsu is recognized for his contributions to medical science.

Collaborations

Shih-Che Hsu collaborates with esteemed colleagues such as Alberto Cerri and Patrizia Ferrari. Their combined expertise fosters an environment of innovation and progress in the field of heart failure treatment.

Conclusion

Shih-Che Hsu's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the development of SERCA2a activators, hold promise for advancing heart failure treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…